Previous close | 0.0500 |
Open | 0.0500 |
Bid | 0.0000 |
Ask | 1.7500 |
Strike | 5.50 |
Expiry date | 2024-07-26 |
Day's range | 0.0500 - 0.0500 |
Contract range | N/A |
Volume | |
Open interest | 52 |
WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data detailing educational needs related to irritable bowel syndrome with constipation (IBS-C) across healthcare disciplines was presented via a poster at the 2024 American Association of Nurse Practitioners (AANP) Annual Confere
With the business potentially at an important milestone, we thought we'd take a closer look at Ardelyx, Inc.'s...
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on May 23, 2024, the compensation committee of the company’s board of directors granted 10 new non-executive employees options to purchase an aggregate of 210,000 shares of the company’s common stock, and granted 13 new non-execut